Schering-Plough buys Millennium's stake in heart drug
Schering-Plough is buying out Millennium Pharmaceuticals' share of the heart drug Integrilin for a minimum of $250.5 million. Of that, $35.5 million will come as an upfront payment with a minimum of $85 million per year for the next two years in royalty payments. Millennium will also pocket $45 million to $50 million for stockpiles of the pharmaceutical.
"Acquiring the balance of US rights to Integrilin will give us direct control of this important therapy in its largest market. This is yet another long-term action we are taking to increase our importance to health providers and patients and to become a global leader in the very important area of cardiac care," said Fred Hassan, Schering-Plough chairman and CEO.
- read this story from TheStreet.com for more
PLUS: Cambridge, Massachusetts-based Millennium swiftly announced that the revised deal with Schering-Plough would lead to the elimination of some 200 jobs. Story
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
